Please login to the form below

Not currently logged in
Email:
Password:

fezolinetant

This page shows the latest fezolinetant news and features for those working in and with pharma, biotech and healthcare.

Bayer moves vilaprisan into phase III trials for uterine fibroids

Bayer moves vilaprisan into phase III trials for uterine fibroids

have acquired Ogeda and its phase IIa candidate Fezolinetant.

Latest news

  • Astellas agrees €800m deal to buy Belgian biotech Ogeda Astellas agrees €800m deal to buy Belgian biotech Ogeda

    Astellas is paying 500m upfront and up to 300m extra in clinical and regulatory milestones for Ogeda (formerly known as Euroscreen) and its lead candidate fezolinetant, which has been shown in ... In a phase IIa trial reported in January, fezolinetant

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    The lead product is a NK3 receptor antagonist (fezolinetant) for treatment of menopause-related vasomotor symptoms (hot flashes).  Fezolinetant successfully completed a phase 2a study in January in 80 menopausal ... regulatory outcomes of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics